Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BHSENASDAQ:CADLNASDAQ:CDTXNYSE:PRME On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHSEBull Horn$9.97$9.63▼$11.19$61.14M-0.0168,771 shs1.18 million shsCADLCandel Therapeutics$4.84-2.6%$6.72$3.79▼$14.60$228.62M-0.951.47 million shs394,486 shsCDTXCidara Therapeutics$21.12+0.4%$20.93$10.14▼$28.42$231.33M0.8971,508 shs79,549 shsPRMEPrime Medicine$1.60-3.6%$1.86$1.12▼$8.27$209.86M1.881.21 million shs901,443 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHSEBull Horn0.00%0.00%0.00%0.00%0.00%CADLCandel Therapeutics-0.20%+10.20%-16.47%-25.82%-22.22%CDTXCidara Therapeutics-2.37%+1.69%-6.07%+11.15%+66.51%PRMEPrime Medicine-1.78%+19.42%-16.58%-41.34%-62.49%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBHSEBull HornN/AN/AN/AN/AN/AN/AN/AN/ACADLCandel Therapeutics2.14 of 5 stars3.51.00.00.02.22.50.6CDTXCidara Therapeutics4.355 of 5 stars4.62.00.04.63.50.80.0PRMEPrime Medicine2.4993 of 5 stars3.60.00.00.01.63.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBHSEBull Horn 0.00N/AN/AN/ACADLCandel Therapeutics 3.00Buy$21.00333.88% UpsideCDTXCidara Therapeutics 3.22Buy$39.1485.34% UpsidePRMEPrime Medicine 3.11Buy$13.38735.94% UpsideCurrent Analyst Ratings BreakdownLatest BHSE, CDTX, CADL, and PRME Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/29/2025CDTXCidara TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$46.00 ➝ $46.004/11/2025CADLCandel TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$19.00 ➝ $19.004/10/2025CDTXCidara TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.00 ➝ $35.003/20/2025PRMEPrime MedicineChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$15.00 ➝ $16.003/19/2025PRMEPrime MedicineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/18/2025PRMEPrime MedicineWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$12.00 ➝ $13.003/14/2025CADLCandel TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$19.00 ➝ $19.003/12/2025CDTXCidara TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform3/12/2025CDTXCidara TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$46.003/12/2025CDTXCidara TherapeuticsCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$46.003/10/2025CDTXCidara TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$24.00 ➝ $35.00(Data available from 4/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBHSEBull HornN/AN/AN/A7.36($0.72) per shareN/ACADLCandel Therapeutics$120K1,905.15N/AN/A$0.44 per share11.00CDTXCidara Therapeutics$1.28M181.43N/AN/A($1.82) per share-11.60PRMEPrime Medicine$2.98M70.35N/AN/A$1.37 per share1.17Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBHSEBull Horn$15.23MN/A0.00N/AN/AN/A-119.46%9.08%N/ACADLCandel Therapeutics-$37.94M-$1.75N/AN/AN/AN/A-629.29%-173.39%5/13/2025 (Estimated)CDTXCidara Therapeutics-$22.93M-$30.09N/AN/AN/A-289.05%-69.64%-33.73%5/8/2025 (Estimated)PRMEPrime Medicine-$198.13M-$1.65N/AN/AN/AN/A-107.87%-74.97%N/ALatest BHSE, CDTX, CADL, and PRME EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025CADLCandel Therapeutics-$0.24N/AN/AN/AN/AN/A5/8/2025Q1 2025CDTXCidara Therapeutics-$5.45N/AN/AN/AN/AN/A3/13/2025Q4 2024CADLCandel Therapeutics-$0.23-$0.40-$0.17-$0.40N/AN/A3/7/2025Full YearPRMEPrime MedicineN/A-$1.65N/AN/AN/AN/A3/6/2025Q4 2024CDTXCidara Therapeutics-$5.28-$5.38-$0.10-$5.37N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBHSEBull HornN/AN/AN/AN/AN/ACADLCandel TherapeuticsN/AN/AN/AN/AN/ACDTXCidara TherapeuticsN/AN/AN/AN/AN/APRMEPrime Medicine$1.4590.37%N/AN/A N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBHSEBull HornN/A0.130.13CADLCandel TherapeuticsN/A1.181.18CDTXCidara TherapeuticsN/A3.543.54PRMEPrime MedicineN/A6.506.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBHSEBull Horn74.95%CADLCandel Therapeutics13.93%CDTXCidara Therapeutics35.82%PRMEPrime Medicine70.37%Insider OwnershipCompanyInsider OwnershipBHSEBull Horn36.60%CADLCandel Therapeutics41.60%CDTXCidara Therapeutics7.64%PRMEPrime Medicine23.47%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBHSEBull Horn25.12 million3.24 millionNot OptionableCADLCandel Therapeutics6047.24 million18.97 millionOptionableCDTXCidara Therapeutics9010.95 million6.51 millionNo DataPRMEPrime Medicine234131.16 million100.38 millionOptionableBHSE, CDTX, CADL, and PRME HeadlinesRecent News About These CompaniesPrime Medicine: Initiating Coverage At Hold With 2025 Binary Catalyst For PM359April 26 at 7:32 AM | seekingalpha.comWhy Prime Medicine, Inc.’s (PRME) Stock Is Down 5.43%April 26 at 7:32 AM | aaii.comPrime Medicine, Inc. (NYSE:PRME) Shares Bought by Walleye Capital LLCApril 22, 2025 | marketbeat.comPrime Medicine, Inc. (NYSE:PRME) Given Average Rating of "Buy" by BrokeragesApril 20, 2025 | americanbankingnews.comPrime Medicine, Inc. (NYSE:PRME) Given Consensus Rating of "Buy" by AnalystsApril 16, 2025 | marketbeat.comPrime Medicine Stock Price, Quotes and ForecastsApril 13, 2025 | benzinga.comWhy Prime Medicine, Inc.’s (PRME) Stock Is Down 12.42%April 5, 2025 | aaii.comWhy Prime Medicine, Inc.’s (PRME) Stock Is Down 10.30%April 2, 2025 | aaii.comPrime Medicine price target raised to $16 from $15 at ChardanMarch 20, 2025 | markets.businessinsider.comWhy Prime Medicine Stock Was Climbing Higher This WeekMarch 20, 2025 | fool.comPrime Medicine Advances AATD Program With Prime Editing For Potential Curative TreatmentMarch 20, 2025 | nasdaq.comWhy Prime Medicine Stock Is Soaring TodayMarch 19, 2025 | fool.comPrime Medicine, Inc.: Promising Future in Gene Editing with Innovative AATD Program and Strategic Growth PotentialMarch 19, 2025 | tipranks.comPrime and Beam, born of same lab, pursuing rival gene-editing treatmentsMarch 19, 2025 | statnews.comPrime Medicine unveils program for treatment of AATDMarch 18, 2025 | markets.businessinsider.comPrime Medicine, Inc.: Innovative Prime Editing Technology and Promising Preclinical Results Drive Buy RatingMarch 18, 2025 | tipranks.comPrime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)March 18, 2025 | globenewswire.comPrime Medicine, Inc.: Strategic Advancements and Promising Financial Outlook Drive Buy RatingMarch 18, 2025 | tipranks.comJ.P. Morgan Reaffirms Their Buy Rating on Prime Medicine, Inc. (PRME)March 4, 2025 | markets.businessinsider.comPrime Medicine Reports 2024 Financial Results and ProgressFebruary 28, 2025 | tipranks.comPrime Medicine, Inc.: Prime Medicine Reports Full Year 2024 Financial Results and Provides Business UpdatesFebruary 28, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBHSE, CDTX, CADL, and PRME Company DescriptionsBull Horn NASDAQ:BHSEBull Horn Holdings Corp. does not have significant operations. It intends to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses in the sports, entertainment, and brands sectors. The company was incorporated in 2018 and is based in Miami Beach, Florida.Candel Therapeutics NASDAQ:CADL$4.84 -0.13 (-2.62%) Closing price 04:00 PM EasternExtended Trading$4.82 -0.02 (-0.41%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.Cidara Therapeutics NASDAQ:CDTX$21.12 +0.09 (+0.43%) Closing price 04:00 PM EasternExtended Trading$21.12 -0.01 (-0.02%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.Prime Medicine NYSE:PRME$1.60 -0.06 (-3.61%) Closing price 04:00 PM EasternExtended Trading$1.58 -0.03 (-1.56%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Coca-Cola Company Stock Can Bubble to New Highs This Year Intel: Good Quarter, Bad Vibes, Guidance Rattles Investors Don’t Be Fooled by the Bounce: The Market Storm Isn’t Over Yet Domino’s Pizza Builds Leverage: Analysts Raise Price Targets 5 Mid-Cap Stocks Insiders Are Buying This Year Alphabet Rebounds After Strong Earnings and Buyback Announcement Occidental’s Hidden Gem: How OxyChem Could Boost Profits T-Mobile US: The Un-Carrier Is an Indisputable Buy on the Dip Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
